Potential biomarker of brain response to opioid antagonism in adolescents with eating disorders: a pilot study.

ABSTRACT:

Background

Eating Disorders (ED) affect up to 5% of youth and are associated with reward system alterations and compulsive behaviors. Naltrexone, an opioid antagonist, is used to treat ED behaviors such as binge eating and/or purging. The presumed mechanism of action is blockade of reward activation; however, not all patients respond, and the optimal dose is unknown. Developing a tool to detect objective drug response in the brain will facilitate drug development and therapeutic optimization. This pilot study evaluated neuroimaging as a pharmacodynamic biomarker of opioid antagonism in adolescents with ED.

Methods

Youth aged 13-21 with binge/purge ED completed functional magnetic resonance imaging (fMRI) pre- and post-oral naltrexone. fMRI detected blood oxygenation-level de

SUBMITTER: Stancil SL 

PROVIDER: S-EPMC10363723 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature